• Palomino Laboratories posted a net loss of USD 1.24 million for the quarter ended March 31, 2026, widening from USD 985,169 a year earlier.
• Operating loss widened to USD 1.24 million from USD 17,828, with total operating expenses rising to USD 1.24 million from USD 17,828.
• General and administrative expense climbed to USD 805,363 from USD 17,828, driven by higher public company costs plus payroll and compensation costs.
• Research and development expense rose to USD 438,240 from none, reflecting a buildout of operations and R&D activities including third-party consulting services plus employee compensation.
• Cash used in operating activities was USD 1.12 million versus cash provided of USD 3,052, with USD 16.98 million in proceeds from an April private placement expected to fund operations for at least 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palomino Laboratories Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023678), on May 15, 2026, and is solely responsible for the information contained therein.